The Molecular Oncology Almanac: Assertion Details

Assertion: Sensitivity to Bosutinib (in Chronic Myelogenous Leukemia)
FDA-Approved

Rearrangement: BCR--ABL1 Fusion

The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy.

Citations:

Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203341s020lbl.pdf. Revised May 2021. Accessed September 16, 2021.

Assertion: Sensitivity to Bosutinib (in Chronic Myelogenous Leukemia) FDA-Approved

FDA-Approved

Assertion: Sensitivity to Bosutinib (in Chronic Myelogenous Leukemia)
FDA-Approved